GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (FRA:B6E) » Definitions » Shiller PE Ratio

Swedish Orphan Biovitrum AB (FRA:B6E) Shiller PE Ratio : 36.46 (As of May. 23, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Shiller PE Ratio?

As of today (2024-05-23), Swedish Orphan Biovitrum AB's current share price is €23.70. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2024 was €0.65. Swedish Orphan Biovitrum AB's Shiller PE Ratio for today is 36.46.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Shiller PE Ratio or its related term are showing as below:

FRA:B6E' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.96   Med: 51.48   Max: 544.45
Current: 36.6

During the past years, Swedish Orphan Biovitrum AB's highest Shiller PE Ratio was 544.45. The lowest was 28.96. And the median was 51.48.

FRA:B6E's Shiller PE Ratio is ranked worse than
69.98% of 533 companies
in the Drug Manufacturers industry
Industry Median: 24.72 vs FRA:B6E: 36.60

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.206. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €0.65 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Swedish Orphan Biovitrum AB Shiller PE Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Shiller PE Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.36 44.07 38.36 33.79 37.27

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.62 30.12 33.00 37.27 35.31

Competitive Comparison of Swedish Orphan Biovitrum AB's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.



Swedish Orphan Biovitrum AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Swedish Orphan Biovitrum AB's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=23.70/0.65
=36.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.206/132.2054*132.2054
=0.206

Current CPI (Mar. 2024) = 132.2054.

Swedish Orphan Biovitrum AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.011 100.432 0.014
201409 0.021 100.161 0.028
201412 -0.007 100.225 -0.009
201503 0.029 99.950 0.038
201506 -0.001 99.995 -0.001
201509 0.002 100.228 0.003
201512 -0.005 100.276 -0.007
201603 0.115 100.751 0.151
201606 0.118 101.019 0.154
201609 0.050 101.138 0.065
201612 0.028 102.022 0.036
201703 0.075 102.022 0.097
201706 0.096 102.752 0.124
201709 0.120 103.279 0.154
201712 0.127 103.793 0.162
201803 0.179 103.962 0.228
201806 0.235 104.875 0.296
201809 0.211 105.679 0.264
201812 0.204 105.912 0.255
201903 0.284 105.886 0.355
201906 0.152 106.742 0.188
201909 0.163 107.214 0.201
201912 0.419 107.766 0.514
202003 0.350 106.563 0.434
202006 0.087 107.498 0.107
202009 0.085 107.635 0.104
202012 0.472 108.296 0.576
202103 0.219 108.360 0.267
202106 0.085 108.928 0.103
202109 0.149 110.338 0.179
202112 0.389 112.486 0.457
202203 0.166 114.825 0.191
202206 0.077 118.384 0.086
202209 0.131 122.296 0.142
202212 0.405 126.365 0.424
202303 0.303 127.042 0.315
202306 0.061 129.407 0.062
202309 0.025 130.224 0.025
202312 0.268 131.912 0.269
202403 0.206 132.205 0.206

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Swedish Orphan Biovitrum AB  (FRA:B6E) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Swedish Orphan Biovitrum AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (FRA:B6E) Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (FRA:B6E) Headlines

No Headlines